- Zacks Small Cap Research•4 hours ago
CytoSorbents (CTSO) has had a busy last couple of months leading up to the annual JP Morgan, Biotech Showcase and Medtech Showcase conferences which were held earlier this week in San Francisco and where management took some time to talk to us. Just prior to the company’s presentation at the Biotech Showcase they announced an expanded agreement with Fresenius and preannounced expected Q4 and FY2016 product sales. Per the January 10th preannouncement, CTSO expects Q4 product sales of ~$2.6M, implying sequential and yoy growth of approximately 21% and 74%, respectively, and marking the sixth straight quarter of record product sales. Product sales of $2.6M is also almost 16% higher than what we had forecast ($2.2M).
- TheStreet.com•19 days ago
Abbott can now proceed with its $25 billion buy of St. Jude Medical.
- GuruFocus.com•2 years ago
Hennessy Japan Fund (Trades, Portfolio) has a highly developed, time-tested investment strategy, looking for arbitrage opportunities between a company’s fundamental value and its market price.
TUO.MU: Summary for TERUMO CORP. - Yahoo Finance
TERUMO CORP. (TUO.MU)
Munich - Munich Delayed price. Currency in EUR
Add to watchlist
As of 8:09AM CET. Market open.
|Bid||33.24 x 14300|
|Ask||34.90 x 13600|
|Day's range||32.89 - 32.89|
|52-week range||32.44 - 38.51|
|PE ratio (TTM)||N/A|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|